Clinical trials: Camrelizumab
Gastrointestinal Cancer, Immunotherapy
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal
At present, surgery, radiotherapy and chemotherapy are the main treatment methods for patients with advanced gastrointestinal cancer.
- Conditions
- Gastrointestinal Cancer, Immunotherapy, Targeted Therapy
- Trial name
- NCT05225844
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Harbin Medical University
Gastric Cancer, AFP
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of PD-1 antibody combined with apatinib mesylate in patients with unresectable, local advanced recurrent or metastatic serum AFP-elevated gastric adenocarcinoma…
- Trial name
- NCT04006821
- Testing
- PD-1 antibody, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Cervical Cancer
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the…
- Trial name
- NCT04906993
- Testing
- camrelizumab； famitinib malate, platinum-based chemotherapy
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatic Metastasis of Colorectal Cancer
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
- Trial name
- NCT04202978
- Testing
- Camrelizumab, Apatinib Mesylate, Capecitabine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhongshan Hospital Xiamen University
Lung Cancer (NSCLC), Neoadjuvant Immunotherapy
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
- Trial name
- NCT06926179
- Testing
- neoadjuvant immunotherapy
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT07251062
- Testing
- SYS6010+SG001+ physician's choice (Capecitabine or 5-FU), Investigator's choice of SOC, SYS6010+SG001
- Volunteers
- 737 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Liver Diseases, Hepatocellular Carcinoma
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and…
- Conditions
- Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
- Trial name
- NCT06061276
- Testing
- bTAE-HAIC, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCE001 (NCT04975932)
- Testing
- TACE+ICIs, TACE
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Zhongda Hospital
NSCLC Stage IV, Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
- Conditions
- NSCLC Stage IV, Brain Metastases, Immunotherapy
- Trial name
- NCT04291092
- Testing
- Immunotherapy, WBRT, Chemotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Effect of Drugs, Progression
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Results of previous study showed high objective response but short-term activity of anti-angiogenesis tyrosine kinase inhibitors in advanced osteosarcoma.
- Conditions
- Effect of Drugs, Progression, Pediatric Cancer
- Trial name
- NCT04044378
- Testing
- Famitinib, Ifosfamide, Camrelizumab
- Where
- China
- Sponsor
- Peking University People's Hospital
Esophageal Malignant Neoplasm, Local Recurrence
Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence
Esophageal cancer is still a serious threat to human life and health. China in particular. Relapse and metastasis are important causes of treatment failure.
- Trial name
- NCT04404491
- Testing
- Procedural death 1, Capecitabine, Radiotherapy
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Non Hodgkin Lymphoma
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion.
- Trial name
- NCT04337606
- Testing
- Chidamide, Decitabine, Camrelizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma
Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer
The study is a multicenter phase II randomized controlled trial. The purpose is to investigate the efficacy and safety of adjuvant immunotherapy combined with chemoradiation for patients with high-risk resectable extrahepatic…
- Conditions
- Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- ACCORD (NCT04333927)
- Testing
- Chemotherapy, Observation, Immunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Breast Cancer
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
This is an open-label, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Gastrointestinal Cancer
- Trial name
- NCT02742935
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HNSCC
Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.
- Trial name
- NCT04861467
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Neoplasms
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.
- Trial name
- DIPPER (NCT03427827)
- Testing
- Camrelizumab
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Hepatocellulcar Carcinoma
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
While immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment…
- Trial name
- NCT07238881
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL
The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib, pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line treatment in patients with de novo stage IE/IIE…
- Trial name
- NCT04366128
- Testing
- CAPA indution immunotherapy
- Where
- 3 sites in China
- Volunteers
- 61 people
- Sponsor
- Rong Tao
Triple-negative Breast Cancer
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
In TNBC patients who have completed neoadjuvant immunotherapy and local treatment, a 9-cycle regimen of PD-1 inhibitor adjuvant immunotherapy is currently considered the standard approach.
- Trial name
- NCT06533384
- Testing
- As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy., 9 cycles of Camrelizumab as adjuvant therapy.
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Guangdong Provincial People's Hospital
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination…
- Trial name
- NCT05156970
- Testing
- Camrelizumab, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University